Titre : Amérique centrale

Amérique centrale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Scleroderma, Localized
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Amérique centrale : Questions médicales les plus fréquentes", "headline": "Amérique centrale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Amérique centrale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Amérique centrale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Amériques", "url": "https://questionsmedicales.fr/mesh/D000569", "about": { "@type": "MedicalCondition", "name": "Amériques", "code": { "@type": "MedicalCode", "code": "D000569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Belize", "alternateName": "Belize", "url": "https://questionsmedicales.fr/mesh/D001531", "about": { "@type": "MedicalCondition", "name": "Belize", "code": { "@type": "MedicalCode", "code": "D001531", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.133" } } }, { "@type": "MedicalWebPage", "name": "Costa Rica", "alternateName": "Costa Rica", "url": "https://questionsmedicales.fr/mesh/D003364", "about": { "@type": "MedicalCondition", "name": "Costa Rica", "code": { "@type": "MedicalCode", "code": "D003364", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.238" } } }, { "@type": "MedicalWebPage", "name": "Salvador", "alternateName": "El Salvador", "url": "https://questionsmedicales.fr/mesh/D004544", "about": { "@type": "MedicalCondition", "name": "Salvador", "code": { "@type": "MedicalCode", "code": "D004544", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.339" } } }, { "@type": "MedicalWebPage", "name": "Guatemala", "alternateName": "Guatemala", "url": "https://questionsmedicales.fr/mesh/D006166", "about": { "@type": "MedicalCondition", "name": "Guatemala", "code": { "@type": "MedicalCode", "code": "D006166", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.454" } } }, { "@type": "MedicalWebPage", "name": "Honduras", "alternateName": "Honduras", "url": "https://questionsmedicales.fr/mesh/D006721", "about": { "@type": "MedicalCondition", "name": "Honduras", "code": { "@type": "MedicalCode", "code": "D006721", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.534" } } }, { "@type": "MedicalWebPage", "name": "Nicaragua", "alternateName": "Nicaragua", "url": "https://questionsmedicales.fr/mesh/D009527", "about": { "@type": "MedicalCondition", "name": "Nicaragua", "code": { "@type": "MedicalCode", "code": "D009527", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.690" } } }, { "@type": "MedicalWebPage", "name": "Panama", "alternateName": "Panama", "url": "https://questionsmedicales.fr/mesh/D010176", "about": { "@type": "MedicalCondition", "name": "Panama", "code": { "@type": "MedicalCode", "code": "D010176", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.107.169.772" } } } ], "about": { "@type": "MedicalCondition", "name": "Amérique centrale", "alternateName": "Central America", "code": { "@type": "MedicalCode", "code": "D002489", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Dylan E Graetz", "url": "https://questionsmedicales.fr/author/Dylan%20E%20Graetz", "affiliation": { "@type": "Organization", "name": "Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee." } }, { "@type": "Person", "name": "Yichen Chen", "url": "https://questionsmedicales.fr/author/Yichen%20Chen", "affiliation": { "@type": "Organization", "name": "Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee." } }, { "@type": "Person", "name": "Meenakshi Devidas", "url": "https://questionsmedicales.fr/author/Meenakshi%20Devidas", "affiliation": { "@type": "Organization", "name": "Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, Tennessee." } }, { "@type": "Person", "name": "Federico Antillon-Klussmann", "url": "https://questionsmedicales.fr/author/Federico%20Antillon-Klussmann", "affiliation": { "@type": "Organization", "name": "National Unit of Pediatric Oncology, Francisco Marroquin University School of Medicine, Guatemala City, Guatemala." } }, { "@type": "Person", "name": "Ligia Fu", "url": "https://questionsmedicales.fr/author/Ligia%20Fu", "affiliation": { "@type": "Organization", "name": "Pediatric Hematology and Oncology Unit, Tegucigalpa School Hospital, Tegucigalpa, Honduras." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Cross-sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument (LoSQI): A disease-specific patient-reported outcome measure.", "datePublished": "2023-04-12", "url": "https://questionsmedicales.fr/article/36950970", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jdv.19059" } }, { "@type": "ScholarlyArticle", "name": "The Reactivation of Scleroderma After Autologous Fat Grafting.", "datePublished": "2023-08-15", "url": "https://questionsmedicales.fr/article/37582285", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/SCS.0000000000009614" } }, { "@type": "ScholarlyArticle", "name": "Scleroderma autoantibodies in guiding monitoring and treatment decisions.", "datePublished": "2022-08-29", "url": "https://questionsmedicales.fr/article/36082759", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/BOR.0000000000000904" } }, { "@type": "ScholarlyArticle", "name": "Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study.", "datePublished": "2023-04-19", "url": "https://questionsmedicales.fr/article/37083160", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.55563/clinexprheumatol/cca0xv" } }, { "@type": "ScholarlyArticle", "name": "Juvenile and adult-onset scleroderma: Different clinical phenotypes.", "datePublished": "2023-03-29", "url": "https://questionsmedicales.fr/article/37031645", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.semarthrit.2023.152197" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Amériques", "item": "https://questionsmedicales.fr/mesh/D000569" }, { "@type": "ListItem", "position": 4, "name": "Amérique centrale", "item": "https://questionsmedicales.fr/mesh/D002489" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Amérique centrale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Amérique centrale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Amérique centrale", "description": "Comment diagnostiquer le paludisme en Amérique centrale ?\nQuels tests pour la dengue ?\nComment identifier la leptospirose ?\nQuels signes indiquent une infection parasitaire ?\nComment diagnostiquer le virus Zika ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Amérique centrale", "description": "Quels sont les symptômes de la dengue ?\nQuels signes de la leptospirose ?\nQuels symptômes du paludisme ?\nComment reconnaître le virus Zika ?\nQuels symptômes d'une infection parasitaire ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Amérique centrale", "description": "Comment prévenir la dengue ?\nQuelles mesures contre le paludisme ?\nComment éviter la leptospirose ?\nQuelles précautions pour le virus Zika ?\nComment prévenir les infections parasitaires ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Amérique centrale", "description": "Quel traitement pour la dengue ?\nComment traiter le paludisme ?\nQuel traitement pour la leptospirose ?\nComment traiter le virus Zika ?\nQuels médicaments pour infections parasitaires ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Amérique centrale", "description": "Quelles complications de la dengue ?\nQuelles complications du paludisme ?\nQuelles complications de la leptospirose ?\nQuelles complications du virus Zika ?\nQuelles complications des infections parasitaires ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Amérique centrale", "description": "Quels sont les facteurs de risque pour la dengue ?\nQuels facteurs de risque pour le paludisme ?\nQuels facteurs de risque pour la leptospirose ?\nQuels facteurs de risque pour le virus Zika ?\nQuels facteurs de risque pour les infections parasitaires ?", "url": "https://questionsmedicales.fr/mesh/D002489?mesh_terms=Scleroderma,+Localized&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer le paludisme en Amérique centrale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins pour détecter le parasite du paludisme." } }, { "@type": "Question", "name": "Quels tests pour la dengue ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests sérologiques et PCR sont utilisés pour confirmer une infection par le virus de la dengue." } }, { "@type": "Question", "name": "Comment identifier la leptospirose ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic est établi par des tests sérologiques et l'historique d'exposition à l'eau contaminée." } }, { "@type": "Question", "name": "Quels signes indiquent une infection parasitaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la diarrhée, la fièvre et la fatigue peuvent indiquer une infection parasitaire." } }, { "@type": "Question", "name": "Comment diagnostiquer le virus Zika ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests sanguins pour détecter le virus ou les anticorps." } }, { "@type": "Question", "name": "Quels sont les symptômes de la dengue ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, douleurs articulaires, éruptions cutanées et fatigue." } }, { "@type": "Question", "name": "Quels signes de la leptospirose ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, maux de tête, douleurs musculaires et éruptions cutanées sont fréquents." } }, { "@type": "Question", "name": "Quels symptômes du paludisme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, sueurs, maux de tête et fatigue sont des symptômes typiques." } }, { "@type": "Question", "name": "Comment reconnaître le virus Zika ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, éruptions cutanées, douleurs articulaires et conjonctivite." } }, { "@type": "Question", "name": "Quels symptômes d'une infection parasitaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les infections parasitaires peuvent causer diarrhée, douleurs abdominales et fatigue." } }, { "@type": "Question", "name": "Comment prévenir la dengue ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éliminer les eaux stagnantes et utiliser des répulsifs contre les moustiques." } }, { "@type": "Question", "name": "Quelles mesures contre le paludisme ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des moustiquaires, des répulsifs et prendre des médicaments préventifs." } }, { "@type": "Question", "name": "Comment éviter la leptospirose ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le contact avec des eaux potentiellement contaminées et porter des bottes." } }, { "@type": "Question", "name": "Quelles précautions pour le virus Zika ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des préservatifs et éviter les zones à risque de moustiques." } }, { "@type": "Question", "name": "Comment prévenir les infections parasitaires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Pratiquer une bonne hygiène, laver les aliments et éviter l'eau contaminée." } }, { "@type": "Question", "name": "Quel traitement pour la dengue ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement est symptomatique, avec des analgésiques et une hydratation adéquate." } }, { "@type": "Question", "name": "Comment traiter le paludisme ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le paludisme est traité avec des antipaludiques comme la chloroquine ou l'artémisinine." } }, { "@type": "Question", "name": "Quel traitement pour la leptospirose ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les antibiotiques comme la doxycycline sont utilisés pour traiter la leptospirose." } }, { "@type": "Question", "name": "Comment traiter le virus Zika ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique ; le repos et l'hydratation sont recommandés." } }, { "@type": "Question", "name": "Quels médicaments pour infections parasitaires ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des antiparasitaires comme le mébendazole ou l'albendazole sont souvent prescrits." } }, { "@type": "Question", "name": "Quelles complications de la dengue ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure la dengue sévère, l'hémorragie et le choc." } }, { "@type": "Question", "name": "Quelles complications du paludisme ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Le paludisme peut entraîner des anémies, des troubles neurologiques et la mort." } }, { "@type": "Question", "name": "Quelles complications de la leptospirose ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions rénales, hépatiques et des hémorragies pulmonaires." } }, { "@type": "Question", "name": "Quelles complications du virus Zika ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Le virus Zika peut causer des malformations congénitales et des troubles neurologiques." } }, { "@type": "Question", "name": "Quelles complications des infections parasitaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les infections parasitaires peuvent entraîner des malnutritions et des troubles digestifs." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour la dengue ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones tropicales, avoir des moustiques et des antécédents d'infection." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le paludisme ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones endémiques, ne pas utiliser de moustiquaires et voyager sans prévention." } }, { "@type": "Question", "name": "Quels facteurs de risque pour la leptospirose ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Travail en milieu rural, contact avec des eaux contaminées et absence de vaccination." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le virus Zika ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones à forte densité de moustiques et absence de protection lors de rapports." } }, { "@type": "Question", "name": "Quels facteurs de risque pour les infections parasitaires ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Conditions d'hygiène précaires, voyage dans des zones endémiques et consommation d'eau contaminée." } } ] } ] }

Sources (10000 au total)

Cross-sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument (LoSQI): A disease-specific patient-reported outcome measure.

The Localized Scleroderma Quality of Life Instrument (LoSQI) is a disease-specific patient-reported outcome (PRO) measure designed for children and adolescents with localized scleroderma (LS; morphea)... The purpose of this study was to evaluate the psychometric properties of the LoSQI in a clinical setting.... Cross-sectional data from four specialized clinics in the US and Canada were included in the analysis. Evaluation included reliability of scores, internal structure of the survey, evidence of converge... One hundred and ten patients with LS (age: 8-20 years) completed the LoSQI. Both exploratory and confirmatory factor analysis supported the use of two sub-scores: Pain and Physical Functioning, and Bo... This study did not evaluate longitudinal validity or responsiveness of scores.... Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is on...

The Reactivation of Scleroderma After Autologous Fat Grafting.

Patients with localized scleroderma (LS) often have to seek plastic surgery to improve facial esthetic impairment.... The authors reported a case of the reactivation of LS after autologous fat grafting (AFG).... A man presented with facial atrophy and skin fibrosis on the cheek with a history of LS. The disease had remained stable for 9 years and he was suggested to stop oral medication. With irreversible est... Six months after the last AFG, the patient found new lesions occur on the lateral forehead. The patient was later diagnosed with reactivation of LS.... The understanding of the surgical risk and perioperative management for patients with LS needs more research....

Scleroderma autoantibodies in guiding monitoring and treatment decisions.

One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia... There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows... ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...

Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study.

People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe... The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys... Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by... People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...

Juvenile and adult-onset scleroderma: Different clinical phenotypes.

Systemic sclerosis (SSc) represents extremely rare disease with majority of data coming from adults. Studies comparing juvenile- (jSSc) and adult-onset (aSSc) patients are limited. We aimed to compare... A retrospective study among pediatric and adult Scl patients has been performed. Demographic characteristics, clinical features, autoantibody profiles, and treatment data were retrieved from the datab... A total of 158 adults and 58 juvenile Scl patients were identified. The mean age at the disease onset was 37±14.7 vs. 8.8 ± 4.1 years, mean age at diagnosis 42±15.2 vs. 10.4 ± 3.8 years and mean follo... Juvenile and adult-onset Scl represent rarely seen conditions with different clinical phenotypes. Pediatric patients with LS are more commonly seen by pediatric rheumatologists, in contrary to adults....

Prevalence of erectile dysfunction in Thai scleroderma patients and associated factors.

Erectile dysfunction (ED) has been reported among patients with systemic sclerosis (SSc) and primarily limited cutaneous SSc in Caucasians. While there is no data on ED among Thais in whom the diffuse... We aimed to estimate the prevalence of ED among Thais with SSc, evaluate its severity, and determine the associated factors.... We did a cross-sectional study among adult Thai male SSc patients. All eligible patients: a) completed the IIEF-15 questionnaire by themselves; b) underwent a genital examination by an experienced uro... A total of 60 male SSc patients were included. The respective mean age and median disease duration was 54.8±7.2 years and 3.1 years (IQR 1.2-7.2). The definition of ED was fulfilled in 53 cases for a ... ED is a common problem in men with SSc and is mainly categorized as severe. The severity of SSc might increase the risk of developing ED. We found phimosis was a common genital abnormality co-occurrin...